Ниволумаб и многофракционная стереотаксическая радиохирургия с ипилимумабом или без него в лечении пациентов с рецидивирующей менингиомой II-III степени
Исследование фазы I/II ниволумаба плюс или минус ипилимумаб в сочетании с многофракционной стереотаксической радиохирургией при рецидивирующей радиационной менингиоме высокой степени злокачественности
This phase I/II trial studies the side effects and best dose of nivolumab when given together with multi-fraction stereotactic radiosurgery and to see how well they work with or without ipilimumab in treating patients with grade II-III meningioma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Giving nivolumab and multi-fraction stereotactic radiosurgery with or without ipilimumab may work better in treating patients with grade II-III meningioma.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
PRIMARY OBJECTIVES:
I. To evaluate the maximum tolerated combination and safety profile of multi-fraction radiosurgery with concurrent nivolumab plus or minus ipilimumab for recurrent radiation-relapsed high-grade meningioma. (Phase I) II. To evaluate the objective response rate (ORR), either complete response or partial response as assessed on magnetic resonance imaging (MRI) per the modified Macdonald Criteria, of multi-fraction radiosurgery with concurrent nivolumab plus or minus ipilimumab for recurrent radiation-relapsed high-grade meningioma. (Phase II)
SECONDARY OBJECTIVE:
I. To evaluate duration of overall response, progression-free survival (PFS) and overall survival (OS) of recurrent radiation-relapsed high-grade meningioma patients treated with the combination of multi-fraction radiosurgery and nivolumab plus or minus ipilimumab.
CORRELATIVE OBJECTIVES:
I. To analyze the immunophenotype changes of peripheral T-cells during the treatment with multi-fraction radiosurgery in combination with nivolumab plus or minus ipilimumab.
II. To perform molecular profiling assays on pretreatment/baseline archival tumor, including, but not limited to, whole exome sequencing (WES) and messenger ribonucleic acid (RNA) sequencing (RNAseq), in order to IIa. Identify potential predictive and prognostic biomarkers (such as neoantigen signature or mutation burden) beyond any genomic alteration by which treatment may be assigned.
IIb. Identify resistance mechanisms using genomic deoxyribonucleic acid (DNA)- and RNA-based assessment platforms.
III. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome.
IV. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the National Cancer Institute Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank).
OUTLINE: This is a phase I, dose-escalation study of nivolumab followed by a phase II study. Patients are randomized to 1 of 2 cohorts.
COHORT A: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
COHORT B: Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo echocardiography (ECHO) as clinically indicated.
After completion of study treatment, patients are followed up for 100 days.
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85054
- Mayo Clinic Hospital in Arizona
-
-
California
-
Duarte, California, Соединенные Штаты, 91010
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, Соединенные Штаты, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Соединенные Штаты, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Соединенные Штаты, 90033
- Los Angeles General Medical Center
-
Orange, California, Соединенные Штаты, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- UCHealth University of Colorado Hospital
-
-
Florida
-
Aventura, Florida, Соединенные Штаты, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Соединенные Штаты, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Соединенные Штаты, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Jacksonville, Florida, Соединенные Штаты, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Соединенные Штаты, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Соединенные Штаты, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Соединенные Штаты, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Kansas
-
Kansas City, Kansas, Соединенные Штаты, 66160
- University of Kansas Cancer Center
-
Westwood, Kansas, Соединенные Штаты, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Mayo Clinic in Rochester
-
-
Missouri
-
Creve Coeur, Missouri, Соединенные Штаты, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Соединенные Штаты, 63110
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68198
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, Соединенные Штаты, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Соединенные Штаты, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
North Carolina
-
Chapel Hill, North Carolina, Соединенные Штаты, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham, North Carolina, Соединенные Штаты, 27710
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
- UPMC Hillman Cancer Center
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Patients must have histologically confirmed World Health Organization (WHO) grade II-III meningioma which has relapsed after prior radiation therapy with radiologically progressive or recurrent disease
-
Patients must have measurable disease, defined as at least 1 lesion that can be accurately measured in at least one dimension as >= 1 cm on brain magnetic resonance imaging (MRI) but with the maximum dimension =< 5 cm OR gross tumor volume < 20 cm^3. All the relapsed disease would need to be eligible to be treated with reirradiation
-
Patients must have at least one prior surgery with available archival formalin-fixed paraffin-embedded (FFPE) tumor blocks of the initial or recurrent meningioma. If there are multiple tumor blocks from multiple surgeries, the most recent tumor block (and ideally of the relapsed tumor after initial radiation therapy) should be submitted. If a tumor block is not available, an alternative of 20-30 unstained slides may be submitted instead. Annotation regarding whether the tumor block is before or after initial radiation therapy should be provided
-
Prior initial radiation therapy may include external beam radiation or radiosurgery, or combination of both. However, the total dose of prior radiation exposure to the site of recurrent tumor (for consideration of re-irradiation) cannot be more than 70 Gy. The duration since the previous radiation exposure to the site of reirradiation need to be at least 6 months
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Leukocytes >= 3,000/mcL
-
Absolute neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN
-
Serum creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 for patients with creatinine levels above 1.5 x institutional normal
-
The effects of nivolumab and/or ipilimumab on the developing human fetus are unknown. For this reason and because radiation therapy is known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP should use an adequate method to avoid pregnancy for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
- WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP use contraception for 5 half-lives plus 100 days
- Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
-
Ability to understand and the willingness to sign a written informed consent document or, if decision-making capacity is impaired, consent of a legally authorized representative (e.g., spouse, adult child, live-in caretaker).
Exclusion Criteria:
-
Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
-
Patients who have had radiation therapy (to the site of reirradiation) within 6 months prior to entering the study
-
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); however, alopecia, sensory neuropathy =< grade 2, or other =< grade 2 not constituting a safety risk based on the investigator's judgment are acceptable
-
Patients who are receiving any other investigational agents
-
Patients who have previous treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab and/or ipilimumab
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
Current use of immunosuppressive medication (EXCEPT for the following: Intranasal, inhaled, topical steroids, or local steroid injection [e.g. intra-articular injection]; systemic corticosteroids at doses =< 4 mg/day of dexamethasone or equivalent; steroids as premedication for hypersensitivity reactions [e.g. computed tomography (CT) scan premedication])
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. However, patients with human immunodeficiency virus (HIV) on stable therapy with minimal viral loads and patients with hepatitis B and hepatitis C who have received treatment with minimal viral loads will be eligible
-
Pregnant women are excluded from this study because radiation therapy is teratogenic and that the effects of nivolumab and/or ipilimumab on the developing human fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with nivolumab and/or ipilimumab, breastfeeding should be discontinued if the mother is treated with nivolumab and/or ipilimumab
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease. Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
- Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
-
Prior organ transplantation including allogeneic stem cell transplantation
-
Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
-
Live vaccination within 4 weeks of the first dose of nivolumab and while on trial is prohibited except for administration of inactivated vaccines
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Cohort A (nivolumab, radiosurgery)
Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated. |
Undergo blood sample collection
Другие имена:
Undergo ECHO
Другие имена:
Given IV
Другие имена:
Undergo brain MRI
Другие имена:
Undergo multi-fraction stereotactic radiosurgery
Другие имена:
|
|
Экспериментальный: Cohort B (nivolumab, ipilimumab, radiosurgery)
Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated. |
Undergo blood sample collection
Другие имена:
Given IV
Другие имена:
Undergo ECHO
Другие имена:
Given IV
Другие имена:
Undergo brain MRI
Другие имена:
Undergo multi-fraction stereotactic radiosurgery
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Максимально переносимая комбинация радиохирургии и ниволумаба плюс или минус ипилимумаб (фаза I)
Временное ограничение: До 100 дней
|
До 100 дней
|
|
|
Частота объективного ответа (Фаза II)
Временное ограничение: С начала лечения и на протяжении как минимум двух лет наблюдения
|
С начала лечения и на протяжении как минимум двух лет наблюдения
|
|
|
Incidence of adverse event profile (Phase I)
Временное ограничение: Up to 100 days
|
Will be evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number and percentage of subjects experiencing each type of adverse event will be tabulated by severity, and relationship to treatment. If appropriate, confidence intervals will be used to characterize the precision of the estimate. A complete listing of adverse events will also be tabulated, and will provide details including severity, relationship to treatment, onset, duration, and outcome. Laboratory data measured on a continuous scale will be characterized by summary statistics (mean and standard deviation). |
Up to 100 days
|
|
Objective radiological response (Phase II)
Временное ограничение: Up to 100 days
|
Will include either complete response or partial response as assessed on magnetic resonance imaging per the modified Macdonald Criteria. 80% confidence intervals will be calculated. |
Up to 100 days
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Длительность общего ответа
Временное ограничение: От начала лечения до как минимум двух лет наблюдения
|
От начала лечения до как минимум двух лет наблюдения
|
|
|
Progression-free survival
Временное ограничение: From the start of treatment to 6 months and 2 years
|
80% confidence intervals will be assessed using Kaplan-Meier product limit methods. |
From the start of treatment to 6 months and 2 years
|
|
Overall survival
Временное ограничение: From the start of treatment through at least two years of follow-up
|
80% confidence intervals will be assessed using Kaplan-Meier product limit methods. |
From the start of treatment through at least two years of follow-up
|
Другие показатели результатов
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Deoxyribonucleic acid sequencing
Временное ограничение: Up to 100 days
|
Will be explored by comparing the differences in theses biomarkers between responders versus non-responders using t-test or Mann-Whitney rank-sum test as appropriate. Permutation test will be used to determine whether the observed difference is larger than might be expected by chance, while the null distribution of test statistics will be generated using 10,000 permutation samples where the response status will be randomly re-shuffled. The observed test statistics will be compared to the null distributions. For each outcome, the permuted p-value will be the fraction of permuted samples that resulted in a small statistic than the original sample. |
Up to 100 days
|
|
Ribonucleic acid expression
Временное ограничение: Up to 100 days
|
Will be explored by comparing the differences in theses biomarkers between responders versus non-responders using t-test or Mann-Whitney rank-sum test as appropriate. Permutation test will be used to determine whether the observed difference is larger than might be expected by chance, while the null distribution of test statistics will be generated using 10,000 permutation samples where the response status will be randomly re-shuffled. The observed test statistics will be compared to the null distributions. For each outcome, the permuted p-value will be the fraction of permuted samples that resulted in a small statistic than the original sample. |
Up to 100 days
|
|
Neoantigen signature
Временное ограничение: Up to 100 days
|
Will be explored by comparing the differences in theses biomarkers between responders versus non-responders using t-test or Mann-Whitney rank-sum test as appropriate. Permutation test will be used to determine whether the observed difference is larger than might be expected by chance, while the null distribution of test statistics will be generated using 10,000 permutation samples where the response status will be randomly re-shuffled. The observed test statistics will be compared to the null distributions. For each outcome, the permuted p-value will be the fraction of permuted samples that resulted in a small statistic than the original sample. |
Up to 100 days
|
|
Changes of peripheral T-cells
Временное ограничение: Baseline up to 100 days
|
Each T-cell subset will be quantified as a percentage of the overall T-cell population by normalizing to CD3+ cells. Linear mixed model for repeated measurement data will be used to assess the change over time as well as the differences between subgroups (e.g., responders vs. non-responders) for immunogenicity and other biomarkers (i.e., frequency of CD8+Ki67+PD1+ T-cells, etc.). Receiver operating characteristic (ROC) curves will also be used to assess the overall predictive ability and to explore the optimal cut-off points for baseline biomarkers to differentiate responders versus non-responders. |
Baseline up to 100 days
|
Соавторы и исследователи
Спонсор
Спонсор
Следователи
Следователи
- Главный следователь: Jiayi Huang, Yale University Cancer Center LAO
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания нервной системы
- Новообразования по локализации
- Новообразования
- Новообразования по гистологическому типу
- Новообразования, нервная ткань
- Новообразования нервной системы
- Новообразования, сосудистая ткань
- Менингеальные новообразования
- Новообразования центральной нервной системы
- Менингиома
- Аминокислоты, пептиды и белки
- Белки
- Следственные методы
- Терапия
- Клинические лабораторные методы
- Диагностические методы и процедуры
- Диагноз
- Хирургические процедуры, оперативные
- Биологические факторы
- Антитела, моноклональные, гуманизированные
- Антитела, моноклональные
- Антитела
- Иммуноглобулины
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Химические методы, аналитические
- Анализ спектра
- Рецепторы, клеточная поверхность
- Мембранные белки
- Лучевая терапия
- Стереотаксические методы
- Нейрохирургические процедуры
- Антигены
- Антигены, поверхность
- Биомаркеры
- Рецепторы, иммунологические
- Антигены, дифференциация, Т-лимфоцит
- Антигены, дифференциация
- Белки иммунной контрольной точки
- Костимуляторные и ингибирующие Т-клеточные рецепторы
- Ниволумаб
- Ипилимумаб
- Обработка образца
- Магнитно -резонансная спектроскопия
- Радиохирургия
- CTLA-4 антиген
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- NCI-2018-01560
- UM1CA186689 (Грант/контракт NIH США)
- UM1CA186704 (Грант/контракт NIH США)
- NCI-2018-01560 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- 201901009
- 10186 (Другой идентификатор: CTEP)
- 10186 (Другой идентификатор: Yale University Cancer Center LAO)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .